Solutions for Purification of Fc-fusion Proteins - When platform processes are applied to fusion molecules, innovation and flexibility are needed - BioPharm International

ADVERTISEMENT

Solutions for Purification of Fc-fusion Proteins
When platform processes are applied to fusion molecules, innovation and flexibility are needed


BioPharm International Supplements


ABSTRACT

Platform processes are valuable tools in process development. Applying them to complex fusion molecules made up of different structures, however, can lead to unexpected results. EA2 is a unique engineered molecule, and it did not fit well into a platform process. It does, however, have three potential affinity and pseudo-affinity sites, each target site having a platform purification unit operation. One site is the antibody Fc region for Protein A binding, but the product was too sensitive to low pHs for typical Protein A elution conditions, so a high pH elution process was developed instead. The other two pseudo-affinity sites proved to be unusable, as did ion exchange chromatography. The final process that was developed added hydrophobic interaction and mixed mode (HIC and AEX) chromatography polishing, with a solvent and detergent (S/D) treatment instead of the typical low pH virus inactivation. This product points out the need for innovation and flexibility in cases where platforms do not work.

Platform processes are powerful and useful tools in process development. Applying them to complex fusion molecules made up of different structures, however, can lead to unexpected results. The process described below is a good example.

The product, designated EA2, is a unique engineered protein and it does not fit into an overall process platform. However, it has three well-known affinity and pseudo-affinity targets, each with well-known binding and elution conditions. Purifications for these targets are unit operations that are used in platform processes. Thus, the development of a purification process was anticipated to be reasonably rapid and simple.

Capture Step

The three targets are the Fc antibody domain target for Protein A, a target for binding to hydroxyapatite, and an enzyme whose active site binds to a dye ligand. Protein A was selected for the initial capture step because it is widely used in bioprocessing.


Table 1. Small-scale low pH Protein A recoveries
The process started with concentration and diafiltration because of its fairly low harvest titer. The concentrated crude bound readily to Protein A, and total recovery of A280 was good. However, recovery of activity was variable, and usually fairly low (Table 1).

Because low pH sensitivity is a common cause of loss of yield off Protein A, a pH stability study was performed (Figure 1a). Based on these results, a pH minimum of 5 was set to provide a safety margin. Even for relatively short exposures, pH levels of 4 and below are to be avoided. This ruled out using low pH for virus inactivation, and makes using low pH elution from Protein A a nonrobust option, even with a short column residence time and immediate neutralization.

It is known that eluate pH will vary between Protein A resins.1,2 Thus, a number of Protein A resins were screened (Table 1). However, in no case was the eluate pH high enough for practical use.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here